1117 related articles for article (PubMed ID: 16322295)
1. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
3. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
[TBL] [Abstract][Full Text] [Related]
4. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
5. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
7. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
[TBL] [Abstract][Full Text] [Related]
8. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
9. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
Cuadros M; Cano C; López FJ; López-Castro R; Concha A
Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
12. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
[TBL] [Abstract][Full Text] [Related]
14. Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category.
Gimbergues P; Dauplat MM; Cayre A; Durando X; Le Bouedec G; Finat-Duclos F; Portefaix G; Kwiatkowski F; Dauplat J; Penault-Llorca F; Tchirkov A
Eur J Surg Oncol; 2007 Feb; 33(1):16-22. PubMed ID: 17071045
[TBL] [Abstract][Full Text] [Related]
15. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
16. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
17. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
18. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
19. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
20. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
Schlemmer BO; Sorensen BS; Overgaard J; Olsen KE; Gjerdrum LM; Nexo E
Scand J Clin Lab Invest; 2004; 64(5):511-22. PubMed ID: 15276916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
